Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 34.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,686 shares of the company’s stock after selling 22,490 shares during the quarter. Primecap Management Co. CA’s holdings in Guardant Health were worth $1,335,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wellington Management Group LLP increased its position in Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Guardant Health during the third quarter valued at approximately $21,389,000. Lord Abbett & CO. LLC purchased a new stake in Guardant Health during the third quarter worth approximately $15,624,000. Two Sigma Advisers LP increased its position in shares of Guardant Health by 52.7% in the third quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock worth $27,007,000 after acquiring an additional 406,500 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Guardant Health by 19.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after acquiring an additional 238,037 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Stock Up 5.5 %

Shares of NASDAQ GH opened at $46.24 on Thursday. The stock’s 50 day moving average price is $43.50 and its two-hundred day moving average price is $33.28. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The stock has a market capitalization of $5.71 billion, a P/E ratio of -12.99 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GH. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Morgan Stanley increased their target price on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. upped their price target on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Scotiabank lifted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Twenty research analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health presently has a consensus rating of “Buy” and an average price target of $48.40.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.